Neuraxis, INC

NRXS · NYSE · SIC 3845: Electromedical & Electrotherapeutic Apparatus
57
SEC Filings

Business Summary

PART I Overview Neuraxis, Inc. (we, us, the Company or Neuraxis) is a first-to-market growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. With several indications in the market and additional clinical trials of Percutaneous Electrical Nerve Field Stimulation (PENFS) in multiple pediatric and adult co...

Next Earnings

Q2 FY2026 — expected 2026-09-08

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionNRXSdiscussed_in_filing Cybersecurity
topic_mentionNRXSdiscussed_in_filing Trusted Computing
topic_mentionNRXSdiscussed_in_filing Blockchain & Crypto
topic_mentionNRXSdiscussed_in_filing Regulation
topic_mentionNRXSdiscussed_in_filing Healthcare & Bio
topic_mentionNRXSdiscussed_in_filing Sovereign & Government
topic_mentionNRXSdiscussed_in_filing Cybersecurity
topic_mentionNRXSdiscussed_in_filing Trusted Computing
topic_mentionNRXSdiscussed_in_filing Blockchain & Crypto
topic_mentionNRXSdiscussed_in_filing Regulation
topic_mentionNRXSdiscussed_in_filing Healthcare & Bio
topic_mentionNRXSdiscussed_in_filing Sovereign & Government
topic_mentionNRXSdiscussed_in_filing Cybersecurity
topic_mentionNRXSdiscussed_in_filing Trusted Computing
topic_mentionNRXSdiscussed_in_filing Blockchain & Crypto
topic_mentionNRXSdiscussed_in_filing Regulation
topic_mentionNRXSdiscussed_in_filing Healthcare & Bio
topic_mentionNRXSdiscussed_in_filing Sovereign & Government
topic_mentionNRXSdiscussed_in_filing Cybersecurity
topic_mentionNRXSdiscussed_in_filing Trusted Computing

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-192025-12-310001493152-26-011505EDGAR88K words
2025-03-202024-12-310001493152-25-010984EDGAR—
2024-04-162023-12-310001493152-24-014832EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-102025-09-300001493152-25-021547EDGAR24K words
2025-08-122025-06-300001641172-25-023100EDGAR—
2025-05-122025-03-310001641172-25-009571EDGAR—
2024-11-122024-09-300001493152-24-044538EDGAR—
2024-08-092024-06-300001493152-24-030875EDGAR—
2024-05-202024-03-310001493152-24-020692EDGAR—
2023-11-202023-09-300001493152-23-042163EDGAR—
2023-09-222023-06-300001493152-23-033460EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2025-10-240001493152-25-019186EDGAR1K words
2025-10-230001493152-25-019136EDGAR—
2025-09-020001641172-25-026158EDGAR—
2025-07-030001641172-25-017723EDGAR—
2025-06-040001641172-25-013632EDGAR—
2025-05-280001641172-25-012698EDGAR—
2025-05-220001641172-25-011973EDGAR—
2025-05-210001641172-25-011939EDGAR—
2025-01-080001493152-25-001323EDGAR—
2024-11-250001493152-24-047623EDGAR—

57 total filings indexed. 36 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

ADMT — ADM TRONICS UNLIMITED, INC. AXGN — Axogen, Inc. BLFS — BIOLIFE SOLUTIONS INC CNMD — CONMED Corp CV — CapsoVision, Inc CBLL — Ceribell, Inc. EDAP — EDAP TMS SA ENDV — ENDONOVO THERAPEUTICS, INC.

Company Identity

CIK0001933567
TickerNRXS
ExchangeNYSE
SIC3845: Electromedical & Electrotherapeutic Apparatus
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 3dbeb5383a11fab717251376b6b9725119a02a77e255ebc17a30a3482fdc2c70
parent: fd9ffe77b11fc64d85d6a8c623e69dbff40adf13cc6b2937588311e12f1463d8
content hash: 539de181c834031fc62c6e6855bbf40ad7c26136f2d409907ef7aef5483f492d
signed: 2026-04-13T04:46:35.162Z
sources: 11 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf